

VISIBLE COHORT A: GUSELKUMAB DEMONSTRATED SKIN CLEARANCE THROUGH WEEK 48 IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS ACROSS ALL SKIN TONES

Andrew Alexis,¹ Adrian O. Rodriguez,² Geeta Yadav,^{3,4} Stephen K. Tying,⁵ Olivia Choi,⁶ Theodore Alkousakis,⁶ Daphne Chan,⁶ Tony Ma,⁷ Maxwell Sauder,^{3,8} Javier Alonso-Llamazares,⁹ Seemal R. Desai,^{10,11}

¹Weill Cornell Medicine, New York, NY, USA; ²Nashville Skin Comprehensive Dermatology Center, Nashville, TN, USA; ³University of Toronto, Toronto, ON, Canada; ⁴FACET Dermatology, Toronto, ON, Canada; ⁵Center for Clinical Studies, Webster, TX, USA; ⁶Janssen Scientific Affairs, LLC, Horsham, PA, USA; ⁷Janssen Research & Development, LLC, Spring House, PA, USA; ⁸Probit Medical Research, Waterloo, ON, Canada; ⁹Driven Research LLC, Coral Gables, FL, USA; ¹⁰Innovative Dermatology, Plano, TX, USA; ¹¹University of Texas Southwestern Medical Center, Dallas, TX, USA



BACKGROUND

VISIBLE is an ongoing, Phase 3b, multicenter, randomized, double-blinded, placebo (PBO)-controlled study of guselkumab (GUS) for the treatment of participants with moderate-to-severe plaque psoriasis (PsO) across all skin tones


VISIBLE comprises 2 cohorts:

Cohort A: participants with moderate-to-severe plaque PsO


Cohort B: participants with moderate-to-severe scalp PsO

VISIBLE was intentionally designed to address historical disparities in clinical trials and enable healthcare professionals to make evidence-based medical decisions for people of all skin tones

OBJECTIVE/METHODS




BASELINE CHARACTERISTICS (N=103)



CONCLUSIONS

- Through Week 48, VISIBLE Cohort A study results showed:
 - >70% of GUS-randomized participants achieved clear/almost clear skin (IGA 0/1 and PASI 90)
 - ≥94% mean % improvement from baseline in BSA and PASI among GUS-randomized participants
 - >50% of GUS-randomized participants achieved complete clearance
 - No new safety signals were identified
 - Clinical responses achieved at Week 16 were maintained or improved through Week 48 with continuous GUS treatment, demonstrating high efficacy and durable responses in participants across all skin tones

RESULTS



PRESENTED AT: Maui Derm Hawaii 2025; Maui, Hawaii, USA; January 20-24, 2025. **Reference:** 1. Alexis A, et al. Poster presented at: Fall Clinical Dermatology Conference; October 19-22, 2023. **Acknowledgments:** Medical writing support was provided by Alyssa Cortina, PharmD, of Janssen Scientific Affairs, LLC under the direction of the authors in accordance with Good Publication Practice guidelines (Ann Intern Med. 2022;175:1298-304). This poster was supported by Janssen Scientific Affairs, LLC, Horsham, PA, USA. Layout design and reformatting for this encore presentation was provided by Mugdha Rokade of SIRO Medical Writing Pvt Ltd, Thane, India. **Disclosures:** AA: has received grants (funds to institution) from AbbVie, Amgen, Arcutis, Castle, Dermavant, Galderma, Incyte, and LEO Pharma; has served on an advisory board or consulted for AbbVie, Allergan, Almirall, Alprolyx, Amgen, Apogee, Arcutis, Avita Medical, Bausch Health, Beiersdorf, Bristol Myers Squibb, Canfield, Cara, Cestra, Cutera, Dermavant, Eli Lilly, Epi, Galderma, Genentech, Genzyme, Incyte, Janssen, LEO Pharma, L'Oréal, Orto, Pfizer, Sanofi-Regeneron, Sun Pharma, UCB, and VisualDx; has served as a speaker for Bristol Myers Squibb, Janssen, Johnson & Johnson, L'Oréal, Regeneron, and Sanofi-Genzyme; has received royalties from Elsevier, Springer, Wiley-Blackwell, and Wolters Kluwer Health; and has received equipment from Aerolase. AOR: has served as an advisor and/or speaker for Arcutis, Dermavant, Eli Lilly, Epi Health, Janssen, LEO Pharma, Novartis, Scion, Sun Pharma, and UCB; owns stock in Strathgryne Crown. GC: is currently a principal investigator for studies being sponsored by AbbVie, Amgen, Arlez, Janssen, Eli Lilly and Sanofi; has served as an advisor for AbbVie, Amgen, Arlez, Janssen, Johnson & Johnson, LEO Pharma, L'Oréal, Medox, Novartis, Pfizer, Sanofi-Regeneron, Sun Pharma, UCB, and Unilever. SKT: has received grants, consultant/speaker honoraria (paid to institution) from AbbVie, Agenus, AlCunis GmbH, Almirall, Amgen, Bayer, Bristol Myers Squibb, Demira, Dr Reddy's Laboratory, Eli Lilly, Foamix Pharma, Galderma, Genocsa Biociences, GlaxoSmithKline Immunology, Glenmark Pharma, IQVIA, Janssen Research & Development, Kiniksa Pharma, LEO Laboratories, Menlo Therapeutics, Merck, Novartis, Parovel, Quintiles Pharma, Regeneron Pharma, Sanofi, Trevi Therapeutics, UCB, and Vical. DC, TA, and DG: are employees of Janssen Scientific Affairs, LLC. TM: is an employee of Janssen Research & Development, LLC; employees may own stock/stock options in Johnson & Johnson, of which Janssen is a subsidiary. MS: has served as an investigator and/or advisor and/or speaker for AbbVie, Alumis, Amgen, Arcutis, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, LEO Pharma, Novartis, Sun Pharma, Takeda, and UCB. JA-L: has served as a speaker for Arcutis, Eli Lilly, Incyte, and UCB; as an advisor for Arcutis and LEO Pharma; and as an investigator for Amgen, Eli Lilly, Janssen, and Takeda. SRD: serves as a consultant and/or investigator for a variety of different organizations including Eli Lilly, Galderma, Incyte, Janssen, L'Oréal, Pfizer and others; serves in numerous leadership capacities within Dermatology. Previously presented at Skin of Color Update 2024; New York, NY, USA; September 13-15, 2024.